MedTrace Logo

Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC

NCT04421469 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2020-06-09

No results posted yet for this study

Summary

This study is a randomized, phase II, prospective, multicenter clinical trial to evaluate the efficacy and tolerability of JS001 and chemotherapy combined with local treatment in patients with multiple metastatic nasopharyngeal carcinoma.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DRUG

Triprilimab(JS001)

1. JS001 240mg d1, gemcitabine(1g/m²),d1,8 + nedaplatin (80-100mg/m²),d2,q3w,6cycles.The curative effect was evaluated every 2 cycles.If the therapeutic evaluation was SD,the chemotherapy scheme was changed; 2. Local treatment of active lesions(including radiotherapy and/or radiofrequency ablation); 3. JS001 maintenance treatment.

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    collaborator OTHER

  • Jiangxi Provincial Cancer Hospital

    collaborator OTHER

  • Fujian Cancer Hospital

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-15
Primary Completion
2023-04-15
Completion
2023-06-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04421469 on ClinicalTrials.gov